Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly'

[
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly'
[og_img]
https://www.investing.com/news/press-releases/scribe-therapeutics-to-highlight-in-vivo-crisprbased-genome-editing-data-for-duchenne-muscular-dystrophy-at-asgct-2025-in-addition-to-joint-presentation-with-prevail-therapeutics-a-part-of-lilly-93CH-4022167


Investing.com